Assertio (ASRT)
(Delayed Data from NSDQ)
$1.54 USD
-0.12 (-7.23%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $1.55 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.54 USD
-0.12 (-7.23%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $1.55 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Assertio (ASRT) Rating Upgrade to Buy
by Zacks Equity Research
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.
Assertio (ASRT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.
Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ASRT) Outperforming Other Medical Stocks This Year?
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $1.14, marking a -1.72% move from the previous day.
ASRT or PCRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $1.07, moving -0.93% from the previous trading session.
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
by Zacks Equity Research
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
by Zacks Equity Research
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
by Zacks Equity Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
ASRT vs. PCRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
by Zacks Equity Research
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
by Zacks Equity Research
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.